Shareholder plans sale of 34951 Akebia shares

A shareholder of Akebia Therapeutics, Inc. has filed a notice of proposed sale of 34951 shares of common stock through Morgan Stanley Smith Barney LLC on the Nasdaq.

Rhea-AI Filing Summary

A shareholder of Akebia Therapeutics, Inc. has filed a notice of proposed sale of 34951 shares of common stock through Morgan Stanley Smith Barney LLC on the Nasdaq. The filing lists an aggregate market value of 48739.00 for these shares.

The shares are part of a much larger base of 265365993 shares outstanding. They were acquired as restricted stock on 01/31/2026, with a listed payment date of 02/02/2026. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for AKBA show about planned share sales?

The Form 144 notice shows a shareholder plans to sell 34951 shares of Akebia Therapeutics common stock. The shares are to be sold on the Nasdaq through Morgan Stanley Smith Barney LLC, with an aggregate market value listed as 48739.00.

How many Akebia Therapeutics (AKBA) shares are outstanding in this Form 144?

The notice reports 265365993 shares of Akebia Therapeutics common stock outstanding. This figure provides context for the planned sale of 34951 shares, indicating the proposed transaction is small relative to the total shares currently outstanding.

How and when were the AKBA shares in this Form 144 acquired?

The filing states the 34951 shares of Akebia common stock were acquired on 01/31/2026 as restricted stock from Akebia Therapeutics, Inc. A payment date of 02/02/2026 is listed, with the nature of payment noted as "n/a."

Which broker and exchange are involved in the AKBA Form 144 sale?

The planned sale will be executed through Morgan Stanley Smith Barney LLC, listed at 1 New York Plaza, 38th Floor, New York, NY 10004. The securities are identified for trading on the Nasdaq exchange as common stock of Akebia Therapeutics.

What is the aggregate market value of the AKBA shares in this Form 144?

The Form 144 notice lists an aggregate market value of 48739.00 for the 34951 Akebia Therapeutics common shares to be sold. This value reflects the total market worth of the planned sale at the time referenced in the filing.

What representations does the seller make in the AKBA Form 144 filing?

The person on whose account the securities are to be sold represents that they do not know any material adverse information about Akebia’s current or prospective operations that has not been publicly disclosed, as part of the standard Form 144 certification language.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 05:58 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001762507
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Akebia Therapeutics, Inc.
SEC File Number	001-36352
Address of Issuer	245 FIRST STREET CAMBRIDGE MASSACHUSETTS 02142
Phone	617-871-2098
Name of Person for Whose Account the Securities are To Be Sold	Ostrowski Erik
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	34951	48739.00	265365993	02/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/31/2026	Restricted Stock	Akebia Therapeutics, Inc.			34951	02/02/2026	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/08/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Carolyn M. Rucci, attorney-in-fact for Erik Ostrowski
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)